SEATTLE, April 29, 2010 –Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE(R) (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen [...] (Source: psa-rising.com/blog)

Original post by psa-rising.com/blog and software by Elliott Back

All mammalian genomes contain genes encoding Apobec proteins. Several members of this protein family (the name stands for apolipoprotein B mRNA editing complex) are induced by interferon and are intrinsic antiretroviral proteins. Apobec proteins inhibit the replication of XMRV, a new human retrovirus associated with prostate cancer and chronic fatigue syndrome.
During retroviral replication, Apobec proteins are packaged into newly synthesized retrovirus particles (illustrated). They exert their antiviral effect when Apobec-containing virions infect a new cell. As the viral reverse transcriptase begins to copy viral RNA into DNA, Apobec removes an amine group from cytosines in single stranded DNA, a process called deamination.  The consequence of deamination is that cytosine is changed to …

Original post by virology blog and software by Elliott Back

Filed under: PreventionSome cancers like breast, colon, prostate and lung cancer run in families. Mutated cancer-causing genes can be passed from parents to children. But family history accounts for only about 5 to 10 percent of most fatal cancers. Even those who have inherited a high-risk genetic mutation like the BRCA-1 or BRCA-2 genes for breast cancer, can protect themselves.
Scientists have identified three types of genes that affect your cancer risk. They are oncogenes, which encourage cells to proliferate in excess; tumor suppressor genes, which normally stop cells from multiplying out of control, but which can become damaged and ineffective; and mismatch-repair genes, which normally help to repair mistakes in DNA, but which can be damaged, allowing mistakes to accumulate.
Other …

Original post by The Cancer Blog and software by Elliott Back

Thereâ??s an old adage in medicine: an ounce of prevention is worth a pound of cure. I couldnâ??t agree more. The problem with a lot of truly preventive medicine is this: thereâ??s not much money in it. The real money (for, say, drug companies) is in treatment. To an extent there can be money too [...] (Source: Dr John Biffa’s Blog)

Original post by Dr John Biffa’s Blog and software by Elliott Back

In light of favorable results from the Phase 1-2 trial of MDV 3100 for advanced prostate cancer, a Phase 3 trial is enrolling at sites in the US, Canada, South America, UK, Europe, Australia, and South Africa. Results from the earlier trial are published online by the UK medical journal The Lancet.
Phase 3 Trial of [...] (Source: psa-rising.com/blog)

Original post by psa-rising.com/blog and software by Elliott Back

Reference :Microcystic Adenocarcinoma of the Prostate: A Variant of Pseudohyperplastic and Atrophic Patterns : Yaskiv, Oksana et al.The American Journal of Surgical Pathology: April 2010 – Volume 34 – Issue 4 – pp 556-561Do you see anything in this prostate that’s worrisome for malignancy? dilated glands admixed with small acini in a noduleI don’t, at least not at this power, and yet this is an example of “microcystic” adenocarcinoma of the prostate. Higher power will show clear-cut cytologic features of malignancy.If this doesn’t concern you about the risk of scanning prostate slides at 4x, it should!Microcystic adenocarcinoma with dilated and crowded glands displaying a predominantly flat lining layerMicrocystic adenocarcinoma with jumbled arrangement of dilated malignant glands.Microcys…

Original post by Oncopathology and software by Elliott Back

Just a follow-up to my previous post, Gene Fusion Prostate Cancer–USCAP 2010, Dr. Rubin's group published their findings of the prevalence of TMPRSS2, SLC45A3, and NDRG1 in a large prostatectomy cohort in the April 2010 Modern Pathology (abstract). (Source: The Daily Sign-Out)

Original post by The Daily Sign-Out and software by Elliott Back